<DOC>
	<DOCNO>NCT02150343</DOCNO>
	<brief_summary>The purpose study compare treatment effect three treatment regimens HDM-SPIRE v placebo evaluate treatment effect HDM-SPIRE symptom , rescue medication usage , Quality Life Sleep Quality</brief_summary>
	<brief_title>Phase II HDM-SPIRE Safety Efficacy Study</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Male female , age 1865 year . Moderate severe rhinoconjunctivitis exposure HDM least 1 year . Mean TRSS ≥10 Positive skin prick test Der p Der f. Dep p Der f specific IgE ≥0.7 kU/L Diagnosis asthma requiringGlobal Initiative Asthma ( GINA ) Step 3 ( www.ginasthma.org ) high treatment FEV1 &lt; 80 % predict . Clinically significant confounding symptom allergy seasonal allergen final evaluation period . Significant symptoms another clinically relevant illness likely affect score rhinoconjunctivitis symptom . Clinically relevant abnormality detect physical examination . History severe drug allergy , severe angioedema anaphylactic reaction food .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Cat allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
</DOC>